Foreign Infectious Disease Expert: "Expecting Success for Enzychem's 'COVID-19 Treatment'... Suppressing Overactive Immune Response"

Professor Cameron Woolf of Duke University, USA, Leads US Government-Supported COVID-19 Emergency Clinical Trials
Clinical Director of EC-18, a COVID-19 Treatment Developed by Enzychem Lifesciences
Professor Woolf: "EC-18 Plays a Key Role in Anti-Inflammation and Suppressing Overactive Immune Responses"

[Asia Economy Reporter Hyungsoo Park] "EC-18 has a mechanism of action that controls the cytokine storm, making it highly likely to succeed as a treatment for the novel coronavirus infection (COVID-19)."

Professor Cameron Woolf of Duke University in the United States said this on the 5th at the 'Coronavirus Expert Panel' held on the Duke University campus, stating, "A true therapeutic drug must have the effect of suppressing the excessive immune response and controlling the cytokine storm."

Professor Woolf is a key opinion leader (KOL) in the development of COVID-19 treatments at Enzychem Lifesciences and also serves as the principal investigator (PI) for clinical trials.

Professor Woolf explained, "EC-18 is a drug targeting the immune system," and "Even if there are antiviral drugs for COVID-19, other immune responses must also be addressed."

He added, "It is presumed that in the late stages of COVID-19, side effects and immune responses cause the patient's condition to deteriorate rapidly around 7 to 8 days after hospitalization," and "EC-18 will play an important role in anti-inflammation and suppression of excessive immune responses."

Professor Nita Parahani of Duke University, who chaired the expert panel, asked about what kind of drug EC-18 is, which Professor Woolf is leading the development of, aside from remdesivir.

Professor Woolf introduced, "EC-18 has a mechanism of action that resolves excessive inflammation and immune responses such as cytokine storms and rapidly normalizes the body's immune function," and "It is a different concept from most other drugs that are immunosuppressants."

He also expressed high expectations for its success as a COVID-19 treatment, saying, "The therapeutic effect for COVID-19 must be proven in phase 2 clinical trials, but it plays a very important role in restoring the patient's condition to a state of homeostasis."

Professor Woolf, an infectious disease expert, is a professor of clinical medicine (MBBS). In February, he published a paper titled 'Coronavirus Disease 2019: Implications of New Infections for Transplantation.' He has published about 60 papers related to infectious diseases, including research on COVID-19, HIV infection, epidemics, influenza, and respiratory virus pathogens. Recently, he has been recognized as one of the top experts in COVID-19 treatment development, leading urgent clinical trials supported by the U.S. government, such as the three-stage remdesivir treatment for severe COVID-19 patients, phase 3 remdesivir studies for moderate COVID-19 patients, and the Adaptive COVID-19 Treatment Trial (ACTT).

This content was produced with the assistance of AI translation services.